🔥Telegram İfşa

Low-Dose Anti-PD1 Immune Checkpoint Inhibitors in Relapsed/Refractory Hodgkin #Lymphoma: A Systematic Review. Read the full article. brnw.ch/21wTgyK #ChildhoodCancer

🚨In The Lancet, Edward Christopher "Chris" Dee, MD & I discuss the need to disaggregate #AsianAmerican data 📊 🔗: bit.ly/4jZERlx The Ten Americas study from Institute for Health Metrics and Evaluation (IHME) reported that Asian Americans had the highest life expectancy, income & education. This framing masks disparities! 1/x

Graduated medschool with honors today👨🏽‍🎓

Nivo-AVD is the new R-CHOP for Hodgkin's ⁦Journal of Clinical Oncology⁩ ascopubs.org/doi/10.1200/JC…

KDIGO is pleased to share the newly published report from its Controversies Conference on Preventing CKD and Maintaining Kidney Health, now available in press in Kidney International. 📄Download the report: kdigo.co/2025-CKD-Preve… 📘 Read the report in KI: kdigo.co/KDIGO-2025-CKD…

Outcomes of Allogeneic HCT in Hodgkin Lymphoma in the Era of Checkpoint Inhibitors: A Joint CIBMTR and EBMT Analysis. Blood Journals Portfolio ashpublications.org/blood/article/…

🚨 Just published in eJHaem Journal A rare but serious complication - acute lung injury in a healthy stem cell donor following G-CSF administration! While rare, this complication may be more likely in smokers and obese individuals. #MedTwitter

📢 Published in Transplantation and Cellular Therapy Journal 🎉 Using a large dataset (CIBMTR + Hans Messner Allogeneic BMT Program), we show that ATG + PTCy may alleviate the ⤴️GvHD risk associated with female donor-to-male recipient MUD transplants 🙌🏽 astctjournal.org/article/S2666-…

Dexamethasone for the management of CRS Related to teclistamab in patients with relapsed/refractory multiple myeloma | Blood Cancer Journal nature.com/articles/s4140…

Just out! Current Risk stratification of all Plasma Cell Disorders. MGUS, SMM, Myeloma, Amyloidosis. We paid Open Access fees so you can download and read freely! Lots of Tables. Bookmark. Saurabh Zanwar Shaji Kumar Leukemia Journal Link: nature.com/articles/s4137…

🫠

#GeriatricAssessment and Management (GAM) plays a pivotal role in improving outcomes for older adults with cancer, and it’s more than just good practice. It’s evidence-based. Check this and all SIOG Guidelines here loom.ly/CC4DtOo #SIOG25 #GeriOnc

Very exciting data for epcoritamab + R2 in RR FL - EPCORE FL-1 RCT preliminary results ir.genmab.com/news-releases/…

📢 Happy to share our latest review on allogeneic transplant for CMML 🙌🏽 link.springer.com/article/10.100…

Such an honor to have contributed to this ASCO Global Guideline on Geriatric Assessment! We aim to support clinicians and policymakers in resource-constrained settings in assessing and addressing the geriatric needs of older patients with cancer. #gerionc

Incluir pacientes en ensayos clinicos es casi siempre la 1era opción en las guías internacionales de linfomas pero el acceso en latinoamerica continúa siendo una excepcion. Jornadas rioplatenses de linfomas.

Thrilled to have 3 abstracts accepted for poster presentation at #ASH25! 🎉 Grateful to my mentors; Perla Colunga for building such an amazing team and to my good friend James Wu | 吴简凡 MD—met through ASH 2 yrs ago and his shared knowledge has been key to these works! 🥳

Proud of you and all the work you put in for our two projects! Excited for you to share our work at #ASH25 🎉🎉 #mmsm #mpnsm #leusm #lymsm #ASHTrainee #GlobalHematology Edward Christopher "Chris" Dee, MD ASH

Low-dose Nivolumab and Lenalidomide in Relapsed/Refractory Hodgkin Lym... sciencedirect.com/science/articl…. Vikram Mathews Uday Kulkarni Phaneendra Datari

Just received some pretty exciting news! 🎉 I’ve been selected to join the The EBMT Trainee Committee Committee! 🥳 Truly an honor. I can’t wait to contribute to this amazing network and learn from the brilliant minds behind it